Kineta, Inc. (NASDAQ:KA – Get Free Report) CFO Keith Baker acquired 5,000 shares of the company’s stock in a transaction dated Monday, September 18th. The shares were bought at an average price of $2.13 per share, for a total transaction of $10,650.00. Following the acquisition, the chief financial officer now directly owns 16,880 shares of the company’s stock, valued at approximately $35,954.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Kineta Price Performance
NASDAQ KA traded up $0.17 during mid-day trading on Tuesday, hitting $2.38. The company’s stock had a trading volume of 30,485 shares, compared to its average volume of 22,090. The company’s 50 day simple moving average is $2.11 and its 200 day simple moving average is $3.05. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.39 and a current ratio of 1.39. Kineta, Inc. has a twelve month low of $1.78 and a twelve month high of $15.54.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Kineta in a report on Monday, August 21st.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. Artal Group S.A. bought a new position in shares of Kineta in the fourth quarter valued at approximately $197,000. Renaissance Technologies LLC bought a new position in Kineta during the 4th quarter valued at $111,000. CIBC Asset Management Inc purchased a new position in Kineta during the 1st quarter worth $45,000. Geode Capital Management LLC purchased a new position in Kineta during the 1st quarter worth $34,000. Finally, BlackRock Inc. grew its stake in shares of Kineta by 236.4% in the 2nd quarter. BlackRock Inc. now owns 20,741 shares of the company’s stock worth $54,000 after acquiring an additional 14,575 shares in the last quarter. 13.66% of the stock is currently owned by institutional investors and hedge funds.
Kineta Company Profile
Kineta, Inc, a clinical-stage biotechnology company, develops immunotherapies in the field of immuno-oncology, cancer, neurology, and arenaviruses. The company is developing KVA12123, an anti-VISTA antagonist mAb immunotherapy, which is in Phase 1/2 clinical trials for the treatment of solid tumors, including non-small cell lung cancer, ovarian cancer, colorectal cancer, colon cancer, pancreatic cancer, and gastric cancer.
- Five stocks we like better than Kineta
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Hold-It-Forever AutoZone Pulls into Buy Zone
- Energy and Oil Stocks Explained
- Virtual Riches: 3 Stocks Leading the VR Revolution
- How to Invest in Virtual Reality
- 5 eCommerce Companies that need to be on Your Watch List
Receive News & Ratings for Kineta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kineta and related companies with MarketBeat.com's FREE daily email newsletter.